Regardless of what is written, or by whom, tomorrow ONC will be doing the now anticipated oral presentation.
Acullly not ONC,but the study team.
Onc management will do a coda, Monday Am, premarket.
speculations?
im not expecting any business development news. THAT, was made clear last CC.
We do need & Im hopefully expecting results exceeding the original phase 2. Certainly needs to be better than, what was presented most recently.
Apparently the 50% improvement, over TAxol alone, is subject to interpretation.( sarcasm intended).
Striping away, 25 years of history & mutiple trials.....
mangament knows full well a B.D. Deal is needed to give any sustained SP increase.
Since, we know that won't be announced Monday, The SP will react to
1. The significance of the oral & up-to-date MBc data.
2. The take away from KOL webinar.
both need to be solid.
Have a great weekend all.
PS
What we don't know is the actual pharma interest?
We als don't know ONCs stratagy.
The written stuff says. " looking towards a phase 3 license deal"
That, could regrettably extend things out until the Pancreatic results.I believe that is expected 2H of this year.
Meaning, anytime between now & Dec 31.
As a long term shareholder. Assuming a quick deal could be done at xxx$ PS.
or wait until a more significant deal with Roche,
That process would bother a lot of people. However in the long run, would produce a significant amount of value.
Again, I'll be looking for clarity on Monday.